In this study, we unexpectedly found that HDAC inhibitor trichostatin A (TSA), but not suberoylanilide hydroxamic acid (SAHA), represses EGFR protein level independently of HDAC inhibition in the lapatinib-treated breast cancer cells. The gene discussed is HDAC9; the disease is breast carcinoma.